SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tentori, L. Articles by Graziani, G. Search for Related Content PubMed PubMed Citation Articles by Tentori, L. Articles by Graziani, G. Related Collections Neoplasia Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 March 2002, Vol. 99, No. 6, pp. 2241-2244 BRIEF REPORT Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site Lucio Tentori, Carlo Leonetti, Marco Scarsella, Giulia d'Amati, Ilaria Portarena, Gabriella Zupi, Enzo Bonmassar, and Grazia Graziani From the Department of Neuroscience, University of Rome Tor Vergata; Istituto Dermopatico dell'Immacolata, Rome; Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome; and Department of Experimental Medicine and Pathology, University of Rome La Sapienza, Italy.     Abstract Top Abstract Introduction Study design Results and discussion References Temozolomide (TZM) is a DNA-methylating agent that has recently been introduced into various clinical trials for treatment of solid or hematologic neoplasias, including brain lymphomas. In the current study, we have investigated whether the antitumor activity of TZM could be selectively enhanced at the central nervous system (CNS) site by intracerebral injection of a poly(ADP-ribose) polymerase (PARP) inhibitor. Mice were injected intracranially with lymphoma cells. The PARP inhibitor NU1025 (1 mg/animal) was delivered intracerebrally, whereas TZM was given as a single or a fractionated dose of 200 mg/kg by intraperitoneal administration. Results indicated that this drug combination significantly enhanced the survival of tumor-bearing mice and that this fractionated modality of treatment was the most effective schedule. Increased survival time was related to a marked reduction of tumor growth, as evidenced by histologic studies. Treatment with TZM alone was ineffective. This is the first report exploring in vivo the combination of TZM with PARP inhibitor for intracerebral neoplasias. (Blood. 2002;99:2241-2244) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Study design Results and discussion References Temozolomide (TZM) is a methylating agent that crosses the blood-brain barrier and is indicated for malignant gliomas and metastatic melanomas.1-3 Moreover, the drug has recently shown promising antitumor activity in a patient affected by primary brain lymphoma4 and is under phase 2 clinical trials for leptomeningeal metastasis from leukemia and lymphoma. However, the antitumor activity of TZM is strongly affected by the functional status of DNA repair systems, involved either in the removal of methyl adducts from O6G or in the apoptotic signaling triggered by O6methylG-C/T mispairs. In particular, TZM is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system (MR).5-7 Resistant leukemia cells become susceptible to TZM when this drug is combined with inhibitors of poly(ADP-ribose) polymerase (PARP), a component of the base excision repair system.8-10 In this case cytotoxicity is caused by interruption of the repair process of N-methylpurines generated by TZM. In the current study, we have investigated whether the antitumor activity of TZM could be selectively potentiated at the CNS site through the use of intracerebral injection of PARP inhibitor.     Study design Top Abstract Introduction Study design Results and discussion References In vitro studies The murine lymphoma cell line L5178Y of DBA/2 (H-2d/H-2d) origin (ATCC, Manassas, VA) was cultured in RPMI-1640 containing 10% fetal calf serum and antibiotics. Inhibition of PARP was obtained by treating cells (105 cells/mL) with 8-hydroxy-2-methylquinazolin-4[3H]-1 (NU1025; Calbiochem, Darmstadt, Germany), at a concentration (25 µM) that abrogates PARP activity.11,12 Cells were then exposed to TZM (7.5-125 µM) (Schering-Plough, Kenilworth, NJ) and were cultured for 3 days. Cell growth was evaluated by counting viable cells in quadruplicate, and apoptosis was assessed by flow cytometry analysis of DNA content.13 Long-term survival was analyzed by colony-formation assay.9 In vivo studies Male B6D2F1 (C57BL/6 × DBA/2) mice were anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg) in 0.9% NaCl solution (10 mL/kg intraperitoneally). L5178Y cells (104 in 0.03 mL RPMI-1640) were then injected intracranially, through the center-middle area of the frontal bone to a 2-mm depth, using a 0.1-mL glass microsyringe and a 27-gauge disposable needle.14 To evaluate tumor cell growth, brains were fixed in 10% phosphate-buffered formaldehyde, and histologic sections (5 µm) were cut along the axial plane, stained with hematoxylin-eosin, and analyzed by light microscopy. TZM was dissolved in dimethyl-sulfoxide (40 mg/mL), diluted in saline (5 mg/mL), and administered intraperitoneally on day 2 after tumor injection at 100 mg/kg or 200 mg/kg, doses commonly used for in vivo preclinical studies.15-17 Because cytotoxicity induced by TZM and PARP inhibitors can be improved by fractionated modality of treatment,9 in selected groups a total dose of 200 mg/kg TZM was divided in 2 doses of 100 mg/kg given on days 2 and 3. NU1025 was dissolved in polyethylene glycol-400 (40% in saline) and was injected intracranially at the maximal deliverable dose (1 mg/mouse, 0.03 mL) or, in selected groups, intraperitoneally (0.3 mL) on day 2 after tumor challenge, 1 hour before TZM administration. Control mice were injected with drug vehicles. Mice were monitored for mortality for 90 days. Median survival time (MST) was determined, and percentage of increase in lifespan (ILS) was calculated as [MST (days) of treated mice/MST (days) of control mice] 1] × 100.18 Efficacy of treatments was evaluated by comparing survival curves between treated and control groups. To assess the ability of different treatments to reduce tumor growth, histologic examination of the brains was performed using additional animals not considered for analysis of survival. Mice were killed at different time points after tumor challenge, selected within the MST range of untreated tumor-bearing animals. Areas of tumor infiltration were measured by histomorphometry, using an automated image analyzer system (Quantimet 520; Leica, Cambridge, United Kingdom). Drug toxicity was evaluated by treating intact mice (10/group) with the compounds under investigation or with vehicles only. Weights and survival times of the mice were recorded for 3 weeks. Animal care was in compliance with international guidelines.19 Statistical analysis Survival curves were generated by the Kaplan-Meier product-limit estimate,20 and statistical differences between the various groups were evaluated by log-rank analysis (software Primer of Biostatistics; McGraw-Hill, New York, NY)     Results and discussion Top Abstract Introduction Study design Results and discussion References In vitro chemosensitivity of L5178Y cells to TZM ± PARP inhibitor Lymphoma cell counts performed 72 hours after treatment showed that the IC50 (confidence limit) of TZM was 44 µM (35-58 µM) when used alone and 16 µM (12-26 µM) when combined with NU1025. Long-term colony assay and apoptosis analysis also showed a more pronounced growth inhibition and cytotoxicity in cells exposed to NU1025+TZM compared with those treated with TZM only (Table 1). Overall the results indicated that the inhibition of PARP markedly enhanced the antitumor activity of TZM, consistent with previous findings in human leukemia cells.8,9                                View this table: [in this window] [in a new window]   Table 1. Influence of NU1025 on apoptosis and colony formation in L5178Y cells treated with TZM Intraperitoneal TZM and intracranial PARP inhibitor enhance survival of mice with intracerebral lymphoma Toxicologic studies showed that no drug-related death occurred in mice treated with TZM (100 or 200 mg/kg) or with NU1025 ± TZM and that the maximal weight loss was 12%. All mice recovered initial body weight 1 week after treatment. Histologic studies were carried out to analyze tumor growth in the brain of untreated animals. Results indicated that lymphoma cells were microscopically evident 2 days after challenge (Figure 1A) and that tumor infiltration in brain parenchyma progressively increased during the following days (Figure 1B-C). Moreover, intracranial injection of L5178Y cells was fatal in 12 to 21 days, and macroscopic evidence of tumor was observed in additional mice killed when moribund. View larger version (192K): [in this window] [in a new window]   Figure 1. Growth characteristics of intracerebral L5178Y lymphoma cells. (A-F) Histologic section stained with hematoxylin-eosin. (A-C) Tumor cell growth in untreated animals. (A) Section obtained from mice killed 2 days after tumor challenge, demonstrates early neoplastic infiltration of the brain. Arrow points to lymphoma cells surrounding a capillary vessel (original magnification, 40 ×). (B) Extensive infiltration, associated with small hemorrhages, is observed in mice killed 4 days after challenge (original magnification, 25 ×). (C) Massive neoplastic infiltration, with brain damage (inset), is detected in mice killed 6 days after challenge (original magnification, 10 ×, inset 40 ×). (D-F) Effects of drug treatment on tumor cell growth. Histologic analysis of untreated or drug-treated mice was performed on day 15 after tumor challenge in additional mice that were not considered for the evaluation of survival (original magnification, 4 ×). Arrows point to hemorrhage and necrosis. (D) Untreated control: massive neoplastic infiltration of the brain. (E) 100 mg/kg TZM on days 2 and 3: diffuse brain infiltration. (F) 100 mg/kg NU1025 + TZM on days 2 and 3: focal collections of neoplastic cells, localized mostly under the leptomeninges, with initial infiltration of the brain tissue. There is no evidence of hemorrhage or necrosis. Tumor cell growth was analyzed by quantitative morphometry of histologic sections (n = 15, 5 animals/group). Results, expressed as mean area (mm2 ± SE) of tumor infiltration, were as follows: untreated control, 6.82 ± 2; TZM, 5.52 ± 1; NU1025 + TZM, 0.058 ± 0.05. Statistical analysis according to unpaired Student's t test: NU1025 + TZM versus untreated controls, P = .00104; NU1025 + TZM versus TZM, P = .000108; TZM versus untreated controls, P = .115. Tumor growth inhibition induced by NU1025 + TZM or by TZM was 99% (range, 98%-99.9%) and 20% (range, 12%-49%), respectively. To determine whether PARP inhibitor, injected at the site of tumor burden, might increase the antitumor activity of TZM administered systemically, animals were treated with NU1025 intracranially and with TZM intraperitoneally. Drug treatment was started on day 2 after challenge, when neoplastic infiltration of the brain tissue was evident in histologic sections. TZM, as a single agent, did not significantly increase MST with respect to control (Table 2). Noteworthy, intracranial injection of NU1025, immediately before the administration of 100 or 200 mg/kg TZM, significantly increased lifespans with respect to controls or to groups treated with TZM only. When TZM was fractionated, the ILS obtained with this schedule was higher than that observed when NU1025 was combined with a single injection of TZM (statistical comparison of survival curves: NU1025 intracranially + TZM 100 mg/kg × 2 vs NU1025 + TZM 200 mg/kg; P = .023). When PARP inhibitor was given intraperitoneally in combination with TZM, no increase in lifespan was observed.                                View this table: [in this window] [in a new window]   Table 2. Influence of NU1025 on survival of animals treated with TZM Figure 2 shows the survival curves of groups treated with the fractionated schedule. The increase in survival detected in the NU1025 + TZM group was indeed related to a statistically significant reduction of tumor growth, as evidenced by histologic studies (Figure 1D-F). On the contrary, a remarkable infiltration of lymphoma cells in the surrounding brain tissue was observed in controls or in mice treated with TZM only. View larger version (17K): [in this window] [in a new window]   Figure 2. Combined treatment with TZM intraperitoneally and PARP inhibitor intracranially increases survival of tumor-bearing mice. Animals (14 per group) were inoculated intracranially with L5178Y lymphoma cells (day 0). Treatment was performed by intracranial injection of NU1025 (1 mg/mouse) or intraperitoneal injection of TZM (100 mg/kg) on day 2 after tumor challenge. An additional dose of TZM was administered on day 3. Control animals (CTR) were treated with drug vehicles only (ie, intracranial polyethylene glycol + intraperitoneal dimethyl sulfoxide) on day 2. Combined treatment with intracranial NU1025 and TZM (100 mg/kg) twice significantly increased survival of tumor-bearing mice with respect to control or TZM-treated groups (P < .0001). Differences between survival curves of mice treated with TZM or NU1025 and survival curve of controls were not statistically significant. The current results demonstrate that intracerebral treatment with NU1025 before the systemic administration of TZM is a new, safe, and effective approach to increase antitumor activity of the methylating agent in the brain. Moreover, fractionated doses of TZM, combined with NU1025, induced a more pronounced antitumor effect compared with an equivalent single dose of TZM + NU1025. It can be speculated that interruption of the repair of N-methylpurines generated by TZM, through the use of PARP inhibitor, might increase tumor cell susceptibility to subsequent TZM administration. It is unlikely that OGAT depletion and elevated O6-methylguanine damage might contribute to the increased efficacy of fractionated schedule because L5178Y cells express low levels of OGAT activity (6.3 fmol/mg protein). When NU1025 was administered intraperitoneally in combination with TZM, no increase in survival was observed. This is likely because of the negative impact of the blood-brain barrier on the distribution of NU1025 into the brain. On the other hand, the intralesional route could be an inadequate strategy against brain lymphoma, considering that the pattern of this malignancy is often diffuse and multifocal. Therefore, formulations of PARP inhibitor that permeate the blood-brain barrier or innovative techniques for drug delivery that provide homogeneous distribution of the compounds into the brain parenchyma21 should be explored. Noteworthy, PARP inhibitors render neoplastic cells susceptible to TZM even in the case of tumors with defective MR or high OGAT levels.8,22 Although OGAT-dependent resistance could be reversed by OGAT inhibitors (ie, O6-benzylguanine23), mutated forms of OGAT enzyme24 might escape inactivation. Furthermore, O6-benzylguanine does not potentiate the activity of TZM in MR-deficient tumors.6,25 Therefore, the use of PARP inhibitors combined with TZM could represent a novel strategy for the control of malignancies localized at the CNS site.     Footnotes Submitted February 22, 2001; accepted October 11, 2001. Supported by grants from the Italian Association for Cancer Research and from the Italian Ministry of Health. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Lucio Tentori, Department of Neuroscience, University of Rome Tor Vergata, Via di Tor Vergata 135, 00133 Rome, Italy; e-mail: tentori{at}uniroma2.it.     References Top Abstract Introduction Study design Results and discussion References 1. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771[Abstract/Free Full Text]. 2. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18:1481-1491[Abstract/Free Full Text]. 3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166[Abstract/Free Full Text]. 4. Reni M, Ferreri AJM, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst. 2000;92:575-576[Free Full Text]. 5. Tentori L, Orlando L, Lacal PM, et al. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol. 1997;52:249-258[Abstract/Free Full Text]. 6. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996;56:5375-5379[Abstract/Free Full Text]. 7. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 1998;54:334-341[Abstract/Free Full Text]. 8. Tentori L, Turriziani M, Franco D, et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia. 1999;13:901-909[CrossRef][Medline] [Order article via Infotrieve]. 9. Tentori L, Portarena I, Vernole P, et al. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol. 2001;47:361-369[CrossRef][Medline] [Order article via Infotrieve]. 10. Tentori L, Portarena I, Bonmassar E, Graziani G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ. 2001;8:457-469[CrossRef][Medline] [Order article via Infotrieve]. 11. Boulton S, Pemberton LC, Porteous JK, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 1995;72:849-856[Medline] [Order article via Infotrieve]. 12. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie. 1995;77:408-422[Medline] [Order article via Infotrieve]. 13. Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia. 1995;9:1888-1895[Medline] [Order article via Infotrieve]. 14. Romani L, Fioretti MC, Bianchi R, Nardelli B, Bonmassar E. Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. J Natl Cancer Inst. 1982;68:817-822. 15. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995;55:2853-2857[Abstract/Free Full Text]. 16. Middleton MR, Kelly J, Thatcher N, et al. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer. 2000;85:248-252[Medline] [Order article via Infotrieve]. 17. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res. 2001;7:421-428[Abstract/Free Full Text]. 18. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000;60:2964-2972[Abstract/Free Full Text]. 19. Guide for Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication N.85-23. 20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 21. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery. 2000;47:1391-1398[Medline] [Order article via Infotrieve]. 22. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and-proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999;5:2908-2917[Abstract/Free Full Text]. 23. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997;3:837-847[Abstract]. 24. Xu-Welliver M, Pegg AE. Point mutations at multiple sites including highly conserved amino acids maintain activity, but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylguanine. Biochem J. 2000;347:519-526[CrossRef][Medline] [Order article via Infotrieve]. 25. Wedge SR, Porteous JK, Newlands ES. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer. 1996;74:1030-1036[Medline] [Order article via Infotrieve]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. M. Horton, G. Jenkins, D. Pati, L. Zhang, M. E. Dolan, A. Ribes-Zamora, A. A. Bertuch, S. M. Blaney, S. L. Delaney, M. Hegde, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity Mol. Cancer Ther., August 1, 2009; 8(8): 2232 - 2242. [Abstract] [Full Text] [PDF] X. Liu, Y. Shi, R. Guan, C. Donawho, Y. Luo, J. Palma, G.-d. Zhu, E. F. Johnson, L. E. Rodriguez, N. Ghoreishi-Haack, et al. Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks Mol. Cancer Res., October 1, 2008; 6(10): 1621 - 1629. [Abstract] [Full Text] [PDF] S. Beneke and A. Burkle Poly(ADP-ribosyl)ation in mammalian ageing Nucleic Acids Res., December 3, 2007; 35(22): 7456 - 7465. [Abstract] [Full Text] [PDF] L. Tentori, C. Leonetti, M. Scarsella, A. Muzi, E. Mazzon, M. Vergati, O. Forini, R. Lapidus, W. Xu, A. S. Dorio, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma FASEB J, August 1, 2006; 20(10): 1709 - 1711. [Abstract] [Full Text] [PDF] D. Martin-Oliva, R. Aguilar-Quesada, F. O'Valle, J. A. Munoz-Gamez, R. Martinez-Romero, R. Garcia del Moral, J. M. Ruiz de Almodovar, R. Villuendas, M. A. Piris, and F. J. Oliver Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis Cancer Res., June 1, 2006; 66(11): 5744 - 5756. [Abstract] [Full Text] [PDF] T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol. Cancer Ther., March 1, 2006; 5(3): 732 - 738. [Abstract] [Full Text] [PDF] C. L. Cheng, S. P. Johnson, S. T. Keir, J. A. Quinn, F. Ali-Osman, C. Szabo, H. Li, A. L. Salzman, M. E. Dolan, P. Modrich, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol. Cancer Ther., September 1, 2005; 4(9): 1364 - 1368. [Abstract] [Full Text] [PDF] E. R. Plummer, M. R. Middleton, C. Jones, A. Olsen, I. Hickson, P. McHugh, G. P. Margison, G. McGown, M. Thorncroft, A. J. Watson, et al. Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 Clin. Cancer Res., May 1, 2005; 11(9): 3402 - 3409. [Abstract] [Full Text] [PDF] L. Tentori, O. Forini, E. Fossile, A. Muzi, M. Vergati, I. Portarena, C. Amici, B. Gold, and G. Graziani N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-{kappa}B DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity Mol. Pharmacol., February 1, 2005; 67(2): 572 - 581. [Abstract] [Full Text] [PDF] C. R. Calabrese, R. Almassy, S. Barton, M. A. Batey, A. H. Calvert, S. Canan-Koch, B. W. Durkacz, Z. Hostomsky, R. A. Kumpf, S. Kyle, et al. Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361 J Natl Cancer Inst, January 7, 2004; 96(1): 56 - 67. [Abstract] [Full Text] [PDF] L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang, et al. Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma Clin. Cancer Res., November 1, 2003; 9(14): 5370 - 5379. [Abstract] [Full Text] [PDF] L. Tentori, I. Portarena, M. Barbarino, A. Balduzzi, L. Levati, M. Vergati, A. Biroccio, B. Gold, M. L. Lombardi, and G. Graziani Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor Mol. Pharmacol., January 1, 2003; 63(1): 192 - 202. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tentori, L. Articles by Graziani, G. Search for Related Content PubMed PubMed Citation Articles by Tentori, L. Articles by Graziani, G. Related Collections Neoplasia Brief Reports Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020